Flortaucipir (18F) is a radiopharmaceutical used for positron emission tomography (PET) imaging in the diagnosis of Alzheimer's disease. It is a radioactive tracer that binds to amyloid plaques, which are a hallmark of Alzheimer's disease, in the brain. The tracer is injected into the bloodstream and travels to the brain, where it is detected by the PET scanner. The scan produces images that reveal amyloid plaques in the brain, enabling physicians to diagnose Alzheimer's disease in patients. Flortaucipir (18F) is the first and only approved PET tracer for the diagnosis of Alzheimer's disease and is used to assess the presence and severity of amyloid plaques in the brain.
Flortaucipir (18F), also commercially available under the brand name Tauvid, is a radioactive diagnostic agent used in conjunction with a medical imaging technique called positron emission tomography (PET) [1, 2]. Here's a breakdown of its key features:
- Function: Flortaucipir (18F) binds specifically to tau protein aggregates in the brain, which are hallmarks of Alzheimer's disease and other neurodegenerative disorders [2, 3]. By attaching to these aggregates, it allows them to be visualized during a PET scan [2].
- Medical use: This radiotracer helps doctors assess the presence and severity of Alzheimer's disease by detecting tau neurofibrillary tangles (NFTs) in the brain [1].
- Benefits: Flortaucipir (18F) provides valuable information about tau pathology, which can aid in differentiating Alzheimer's disease from other forms of dementia [2].
Important points to remember:
- A positive Flortaucipir (18F) scan indicates the presence of tau tangles but doesn't confirm Alzheimer's disease definitively [2].
- This imaging technique is primarily used for adults undergoing evaluation for Alzheimer's disease and not for diagnosing chronic traumatic encephalopathy (CTE) [1].
- Flortaucipir (18F) is radioactive and requires specialized facilities and trained personnel for administration and PET scan interpretation [2].